Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

KEYMED Aktie

 >KEYMED Aktienkurs 
7.875 EUR    (TradegateBSX)
Ask: 8.05 EUR / 371 Stück
Bid: 7.7 EUR / 391 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
KEYMED Aktie über LYNX handeln
>KEYMED Performance
1 Woche: +16,7%
1 Monat: +53,7%
3 Monate: +34,6%
6 Monate: -3,4%
1 Jahr: +40,0%
laufendes Jahr: +34,0%
>KEYMED Aktie
Name:  KEYMED BIOSCIENCES -,0001
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG5252B1023 / A3CTJD
Symbol/ Ticker:  64Z (Frankfurt)
Kürzel:  FRA:64Z, ETR:64Z, 64Z:GR
Index:  -
Webseite:  https://www.keymedbio.com..
Profil:  Keymed Biosciences Inc. is a biopharmaceutical company specializing in the research, development, and commercialization of innovative medical treatments. The company's primary focus is on developing novel therapeutic products aimed at addressing unme..
>Volltext..
Marktkapitalisierung:  2078.57 Mio. EUR
Unternehmenswert:  1935.6 Mio. EUR
Umsatz:  86.13 Mio. EUR
EBITDA:  -61.04 Mio. EUR
Nettogewinn:  -63.49 Mio. EUR
Gewinn je Aktie:  -0.22 EUR
Schulden:  97.74 Mio. EUR
Liquide Mittel:  67.3 Mio. EUR
Operativer Cashflow:  86.74 Mio. EUR
Bargeldquote:  2.35
Umsatzwachstum:  46.64%
Gewinnwachstum:  10.12%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  KEYMED
Letzte Datenerhebung:  04.04.26
>KEYMED Kennzahlen
Aktien/ Unternehmen:
Aktien: 294.6 Mio. St.
Frei handelbar: 70.17%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 1625
Umsatz/Mitarb.: 0.05 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 62.5%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 73.9%
Gewinnmarge: -73.72%
Operative Marge: -84.61%
Managementeffizenz:
Gesamtkaprendite: -13.11%
Eigenkaprendite: -19.94%
>KEYMED Peer Group
Gesundheit, Augenmedizin, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung
 
26.03.26 - 14:57
Keymed Biosciences Announces 2025 Annual Results and Business Updates (PR Newswire)
 
BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. Total revenue in 2025 was approximately RMB 720 million, a 67% year-on-year increase. This included around RMB 310 million from sales of the core product Kangyueda® and......
24.03.26 - 08:54
Rights to antibody drug by China′s Keymed change hands in Gilead acquisition of Ouro (SCMP)
 
US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China's Keymed Biosciences, in a deal worth up to US$2.18 billion. Gilead Sciences is among a group of global drug makers facing patent expirations and turning to mergers, acquisitions and licensing deals to refill their drug pipelines. Under the agreement, Gilead Sciences would pay shareholders of US-based Ouro Medicines US$1.675 billion......
24.03.26 - 06:15
Keymed Biosciences shares rise on $320 mln windfall from Gilead-Ouro deal (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
24.03.26 - 02:45
KEYMED BIO-B Sells ~15% Stake in Ouro Medicines (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
10.03.26 - 10:30
KEYMED BIO-B Receives USD45M Milestone Payment for CMG901 License Agreement (AAStocks)
 
KEYMED BIO-B (02162.HK) announced that AstraZeneca had initiated a multi-center, randomized, controlled Phase III clinical study of sonesitatug vedotin (AZD0901, or CMG901) in combination with capecitabine, with or without rilvegostomig for the first-line treatment of Claudin 18.2-positive and HER2-negative advanced/metastatic g......
05.09.25 - 10:15
Full-day Takeaway: HSI Up 359 pts; HSTI Up 108 pts; XINYI SOLAR Up over 7%; SINO BIOPHARM, CHOW TAI FOOK, CALB, 3SBIO, KEYMED BIO-B Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 359 pts or 1.4% to 25,417. HSTI rose 108 pts or 1.9% to 5,687. HSCEI gained 120 pts or 1.3% to 9,057. Market turnover reached $299.95 billion.Active Heavyweights:TENCENT (00700.HK) closed at $605.5, up 2.2%MEITUAN (03690.HK) closed at $103, up 1.6%BABA (09988.HK) closed at $131.8, up 1.5%XIAOMI (01810.HK) clos......
27.08.25 - 08:21
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum (PR Newswire)
 
CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its......
05.08.25 - 10:30
Full-day Takeaway: HSI Closes at 24,902, Up 169 pts; HSTI Closes at 5,521, Up 39 pts; BYD ELECTRONIC Up over 7%; XD INC, LEPU BIO, KEYMED BIO-B, AKESO, SKB BIO-B Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 169 pts or 0.7% to 24,902. HSTI rose 39 pts or 0.7% to 5,521. HSCEI gained 57 pts or 0.6% to 8,951. Market turnover reached $229.40 billion.Active Heavyweights:TENCENT (00700.HK) closed at $559, up 1.6%CCB (00939.HK) closed at $8, up 1%PING AN (02318.HK) closed at $54.05, up 0.7%XIAOMI (01810.HK) closed at $54......
17.07.25 - 10:30
Full-day Takeaway: HSI Closes at 24,498, Down 18 pts; HSTI Closes at 5,448, Up 30 pts; BEIGENE Up over 10%; BEIGENE, SINO BIOPHARM, HANSOH PHARMA, JOHNSON ELEC H, KEYMED BIO-B Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI dropped 18 pts or 0.1% to 24,498. HSTI rose 30 pts or 0.6% to 5,448. HSCEI fell 8 pts or 0.1% to 8,853. Market turnover reached $236.41 billion.Active Heavyweights:XIAOMI (01810.HK) closed at $56.15, down 2%BABA (09988.HK) closed at $112.5, down 1.1%MEITUAN (03690.HK) closed at $125.5, up 1.1%CCB (00939.HK) closed ......
17.07.25 - 06:15
Midday Takeaway: HSI Closes Midday at 24,534, Up 17 pts; HSTI Closes Midday at 5,434, Up 15 pts; BEIGENE Up over 8%; BEIGENE, HANSOH PHARMA, CHINAHONGQIAO, JOHNSON ELEC H, KEYMED BIO-B Hit New Highs (AAStocks)
 
At midday close, HSI rose 17 pts or 0.1% to 24,534. HSTI rose 15 pts or 0.3% to 5,434. HSCEI gained 4 pts or 0.0% to 8,865.Active Heavyweights:MEITUAN (03690.HK) closed at $126.2, up 1.7%XIAOMI (01810.HK) closed at $56.45, down 1.5%BABA (09988.HK) closed at $113.1, down 0.6%TENCENT (00700.HK) closed at $516, down 0.1%HSI & HSCEI......
13.06.25 - 11:06
Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine (PR Newswire)
 
CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical......
11.06.25 - 04:45
KEYMED BIO-B Places Shrs at 6.5% Discount to Raise HKD850M+ Net Proceeds; Controlling Shareholder Cuts Stake (AAStocks)
 
KEYMED BIO-B (02162.HK) has announced a share placement where Bo CHEN, the company's major shareholder, executive director, and CEO, placed 21.6 million existing shares at HKD45.48 per share (around 7.72% of the issued share capital), marking a discount of about 6.52% to yesterday's (10th) closing price.At the same time,......
25.04.25 - 05:54
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers (PR Newswire)
 
CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") recently announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug......
06.04.25 - 04:15
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine (PR Newswire)
 
CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody......
05.04.25 - 16:18
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine (PR Newswire)
 
CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody......
02.04.25 - 10:15
Full-day Takeaway: HSI Closes at 23,202, Down 4 pts; HSTI Closes at 5,426, Up 19 pts; CHOW TAI FOOK Up over 10%; WH GROUP, LEAPMOTOR, KEYMED BIO-B, CZBANK, CQRC BANK Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI dropped 4 pts or 0.0% to 23,202. HSTI rose 19 pts or 0.4% to 5,426. HSCEI fell 5 pts or 0.1% to 8,531. Market turnover reached $216.60 billion.Active Heavyweights:HKEX (00388.HK) closed at $353.8, up 1.7%CCB (00939.HK) closed at $6.93, up 0.3%BABA (09988.HK) closed at $130, up 0.2%MEITUAN (03690.HK) closed at $157.......
02.04.25 - 06:15
Midday Takeaway: HSI Closes Midday at 23,221, Up 14 pts; HSTI Closes Midday at 5,438, Up 31 pts; CHOW TAI FOOK Up over 5%; LEAPMOTOR, CHINA EAST EDU, CQRC BANK, CZBANK, KEYMED BIO-B Hit New Highs (AAStocks)
 
At midday close, HSI rose 14 pts or 0.1% to 23,221. HSTI rose 31 pts or 0.6% to 5,438. HSCEI gained 1 pts or 0.0% to 8,538.Active Heavyweights:HKEX (00388.HK) closed at $351.8, up 1.1%MEITUAN (03690.HK) closed at $157.7, down 0.1%TENCENT (00700.HK) closed at $503.5, down 0.1%BABA (09988.HK) closed at $129.9, up 0.1%HSI & HSCEI C......
26.03.25 - 16:12
Keymed Biosciences Announces Annual Results of 2024 (PR Newswire)
 
CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) Three new drug applications of......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!